RecruitingPhase 2NCT05389215
Clinical Trial to Evaluate the Safety and Efficacy of DWN12088 in Patients With IPF
Studying Idiopathic pulmonary fibrosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
- Principal Investigator
- SongAIDS Malignancy Consortium
- Intervention
- DWN12088(drug)
- Enrollment
- 102 target
- Eligibility
- 40 years · All sexes
- Timeline
- 2022 – 2027
Study locations (30)
- Pulmonary Associates, PA, Mesa, Arizona, United States
- Dignity Health Norton Thoracic Institute, Phoenix, Arizona, United States
- The University of California San Francisco, San Francisco, California, United States
- Loyola University Medical Center (LUMC), Maywood, Illinois, United States
- University of Kansas Medical Center Research Institute, Inc, Kansas City, Kansas, United States
- Tufts Medical Center, Boston, Massachusetts, United States
- Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
- University of Michigan Health System, Michigan Center, Michigan, United States
- The Lung Research Center, LLC, Chesterfield, Missouri, United States
- Duke University Medical Center, Durham, North Carolina, United States
- Pulmonix Research, LLC, Greensboro, North Carolina, United States
- Legacy Research Institute, Portland, Oregon, United States
- Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States
- University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
- The U.S. Department of Veterans Affairs, Charleston, South Carolina, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05389215 on ClinicalTrials.govOther trials for Idiopathic pulmonary fibrosis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT05988463Dose-Escalation Study of Artesunate Patients With IPFJoseph C. Wu
- RECRUITINGNANCT07486206Optimizing the Follow-Up Journey in Interstitial Lung Disease: The OPTIMIZE-ILD-2 TrialHospital de Granollers
- RECRUITINGNANCT07482917Optimizing the Diagnostic Journey in Interstitial Lung Disease: The OPTIMIZE-ILD-1 TrialHospital de Granollers
- RECRUITINGPHASE2NCT06241560A Study in People With Idiopathic Pulmonary Fibrosis to Test Whether Pirfenidone Influences the Amount of BI 1015550 in the BloodBoehringer Ingelheim
- RECRUITINGPHASE3NCT07201922A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary FibrosisBoehringer Ingelheim
- RECRUITINGNANCT07466420Study on the Efficacy of Quercetin Intake in Patients With Fibrotic Interstitial Lung Diseases.Katerina M. Antoniou
- RECRUITINGPHASE3NCT07299695Intravenous Immunoglobulin for the Treatment of Acute Exacerbations of Idiopathic Pulmonary FibrosisArgyrios Tzouvelekis
- RECRUITINGPHASE2NCT07284459Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary FibrosisContineum Therapeutics